Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression حسب Julia Cataldo Lima (22811497)

"…</p> <p>To investigate this, we analyzed the expression of interferon-stimulated genes (ISGs) in 48 SARS-CoV-2-infected patients using real-time polymerase chain reaction (RT-qPCR) and assessed toll-like receptor (TLR7) expression in blood cells via flow cytometry.…"

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Naringenin decreases total cell viability. حسب Lauren A. Eanes (20995499)

<b>When more isn’t better: Sperm competition decreases fertilization success and motile sperm in two sea urchin species</b> حسب Luisa Kumpitsch (20874095)

"…<p dir="ltr">Abstract of the paper "<b>When more isn’t better: Sperm competition decreases fertilization success and motile sperm in two sea urchin species":</b></p><p dir="ltr">Fertilization is a fundamental process where sperm-egg fusion is essential to maintain life of most metazoans. …"

Disruption of putative host factor LGMN decreases SARS-CoV-2 viral entry. حسب Ravi K. Dinesh (21736629)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. حسب Erienne G. Norton (9612079)

RcbA and RcbB co-operatively decrease motility independent of CaCl₂ concentration. حسب Shobnom Mustaree (21728815)

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" حسب Kira Shaw (18796168)

"…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …"

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات: